Atossa Therapeutics (NASDAQ:ATOS) announced its decision to pursue a metastatic breast cancer (MBC) indication for (Z)-endoxifen.
According to Attosa, it also plans to work with the FDA to advance additional indications, such as breast cancer prevention and neoadjuvant therapy, which often require large, lengthy trials.
Dr. Steven Quay, chairman and CEO of Atossa, commented, “Our decision to advance (Z)-endoxifen into a MBC indication underscores our unwavering commitment to developing a best-in-class therapy for women facing this devastating disease.”
He added, “The encouraging clinical data that has been generated to date supports the potential of (Z)-endoxifen to provide a meaningful benefit to patients who have exhausted other treatment options. By pursuing this strategy, we believe we are not only pursuing an urgent medical need but also fortifying the path forward for expanding (Z)-endoxifen’s role across the full spectrum of breast cancer prevention and treatment. We look forward to providing future updates as we execute this plan.”
